Xoma Corp. (NASDAQ:XOMA) has been assigned an average recommendation of “Hold” from the six analysts that are currently covering the stock. Five equities research analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $2.50.
Several research firms have commented on XOMA. Cowen and Company restated a “market perform” rating on shares of Xoma Corp. in a report on Monday, September 19th. Wedbush restated an “outperform” rating and issued a $3.00 price target (up previously from $1.42) on shares of Xoma Corp. in a report on Friday, September 16th. Zacks Investment Research cut Xoma Corp. from a “buy” rating to a “hold” rating in a report on Friday, August 26th. Finally, Jefferies Group restated a “hold” rating on shares of Xoma Corp. in a report on Friday, August 5th.
Hedge funds and other institutional investors have recently modified their holdings of the company. Paloma Partners Management Co purchased a new position in shares of Xoma Corp. during the second quarter valued at $185,000. Spark Investment Management LLC raised its position in shares of Xoma Corp. by 100.9% in the second quarter. Spark Investment Management LLC now owns 203,900 shares of the company’s stock valued at $112,000 after buying an additional 102,400 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Xoma Corp. by 19.6% in the second quarter. Vanguard Group Inc. now owns 5,321,901 shares of the company’s stock valued at $2,934,000 after buying an additional 871,594 shares during the last quarter. Wedbush Securities Inc. raised its position in shares of Xoma Corp. by 4.1% in the second quarter. Wedbush Securities Inc. now owns 404,396 shares of the company’s stock valued at $223,000 after buying an additional 15,827 shares during the last quarter. Finally, Bellevue Group AG purchased a new position in shares of Xoma Corp. during the first quarter valued at $174,000. 17.13% of the stock is currently owned by institutional investors.
Shares of Xoma Corp. (NASDAQ:XOMA) opened at 0.4181 on Tuesday. The stock has a market capitalization of $50.42 million, a price-to-earnings ratio of 38.0091 and a beta of 2.87. Xoma Corp. has a 1-year low of $0.40 and a 1-year high of $2.03. The company’s 50 day moving average is $0.53 and its 200-day moving average is $0.64.
Xoma Corp. (NASDAQ:XOMA) last posted its quarterly earnings data on Wednesday, August 3rd. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by $0.01. The company earned $0.40 million during the quarter, compared to analysts’ expectations of $0.84 million. During the same period in the previous year, the company posted ($0.20) EPS. Equities analysts anticipate that Xoma Corp. will post ($0.47) earnings per share for the current fiscal year.
Xoma Corp. Company Profile
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
Receive News & Ratings for Xoma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xoma Corp. and related companies with MarketBeat.com's FREE daily email newsletter.